A significant number of Swiss biotechs exhibit in Boston

The BIO International Convention awaits more than 14,000 biotechnology and pharma leaders in Boston for one week of intensive networking to discover new opportunities and promising partnerships. Last year 10'000+ companies from all over the world were represented, with 1900 exhibiting.

Switzerland will again attend to demonstrate why the country has continued spearheading the Global Innovation Index. The Swiss delegation of 46 companies will exhibit at the Swiss Biotech Pavillion, organized by Switzerland Global Enterprise, Presence Switzerland, the Swiss Biotech Association, Innosuisse, Swissnex and the Swiss Business Hub USA. Among them are 25 Swiss startups, of which 13 will receive support from Innosuisse, the Swiss Innovation Agency.

The conference's theme, "Stand up for Science", is well-reflected in the range and depth of innovation showcasing a diverse array of first-in-class therapeutic Biotech Swiss companies and startups, which spans the entire drug discovery and development process, from the analysis of omics data to the utilization of AI in designing clinical. Participating in the convention will expose the startups to players in the global life sciences sector and get the opportunity to discuss potential collaborations.

Startups supported by Innosuisse are:

Acthera Therapeutics –  targeted drug delivery for acute cardiovascular events

ASTRA Therapeutics –  precision drug engineering across the whole range of parasitic diseases

Cellestia – first-in-class  cancer gene therapies

Cellvie –  therapeutic mitochondria transplantation

Endothelix Therapeutics – solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies

GaDia – rapid in vitro diagnostic (IVD) test to detect nosocomial disease

Incephalo – Next-generation therapies for brain cancers

MPC Therapeutics – cellular rejuvenation to fight cancer and degenerative pathologies

PreComb Therapeutics – evidence-based therapy prediction for cancer drug discovery and therapy guidance using 3D tumour modelling and its 3DTwin technology

REM Analytics – unique method of DNA analysis to assess microbiome composition, food authenticity and food safety.

Risklick – AI-driven clinical trial design

Synendos – new class of small molecules for treating a wide range of Central Nervous System (CNS) disorders. 

Vandria – Mitophagy inducers to treat age-related and chronic diseases

Other startups at the convention are:

Ariadne.ai  –  the fastest way to analyze thousands of biomedical images

Aurealis Therapeutics – multi-target cell and gene therapy platform. First candidates for chronic wounds and cancers

Ceidos – On-line, automated and real-time cell analysis

EvlaBio – development of drug programs including antibody programs for the treatment of hepatocellular carcinoma and chronic kidney disease

FluoSphera - multi-tissue test systems using the precision of fluorescent light to mimic communications between human organs

ImmunSkills – allogenic cell therapy for solid cancers

Novochizol – Nanospheres which can be used alone for their anti-inflammatory and immune-stimulating properties or as bioadherent carriers.

Orio Therapeutics – therapeutic proteins with improved delivery through controlled localization, for enhanced efficacy and reduced dosage.

PDC Therapeutics –smart nanomedicines for targeted therapies via a Polymer Drug Conjugate technology

Sefunda – rapid PCR test platform to be used at the point of care

ten23 health – global contract development and manufacturing organization